181 related articles for article (PubMed ID: 31557162)
1. Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Goyal V; Burza S; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Das VNR; Bern C; Hightower A; Rijal S; Sunyoto T; Alves F; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007726. PubMed ID: 31557162
[TBL] [Abstract][Full Text] [Related]
2. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Goyal V; Mahajan R; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Alves F; Rabi Das VN; Topno RK; Sharma B; Balasegaram M; Bern C; Hightower A; Rijal S; Ellis S; Sunyoto T; Burza S; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006830. PubMed ID: 30346949
[TBL] [Abstract][Full Text] [Related]
3. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
5. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
6. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
7. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
[TBL] [Abstract][Full Text] [Related]
8. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India.
Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2603. PubMed ID: 24392168
[TBL] [Abstract][Full Text] [Related]
9. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Olliaro P; Sundar S
Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
[TBL] [Abstract][Full Text] [Related]
10. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
11. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
12. A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy.
Kumar N; Sinha PK; Pandey K; Verma N; Lal CS; Ranjan A; Verma RB; Das P
Int J Clin Pharm; 2011 Oct; 33(5):726-9. PubMed ID: 21833710
[TBL] [Abstract][Full Text] [Related]
13. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
Patole S; Burza S; Varghese GM
Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
[TBL] [Abstract][Full Text] [Related]
14. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
[TBL] [Abstract][Full Text] [Related]
15. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
Rodrigo C; Weeratunga P; Fernando SD; Rajapakse S
Clin Microbiol Infect; 2018 Jun; 24(6):591-598. PubMed ID: 29138100
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India.
Burza S; Sinha PK; Mahajan R; Lima MA; Mitra G; Verma N; Balasegaram M; Das P
PLoS Negl Trop Dis; 2014; 8(1):e2536. PubMed ID: 24392166
[TBL] [Abstract][Full Text] [Related]
17. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
18. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
19. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia.
Ostyn B; Hasker E; Dorlo TP; Rijal S; Sundar S; Dujardin JC; Boelaert M
PLoS One; 2014; 9(6):e100220. PubMed ID: 24941345
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
Diro E; Blesson S; Edwards T; Ritmeijer K; Fikre H; Admassu H; Kibret A; Ellis SJ; Bardonneau C; Zijlstra EE; Soipei P; Mutinda B; Omollo R; Kimutai R; Omwalo G; Wasunna M; Tadesse F; Alves F; Strub-Wourgaft N; Hailu A; Alexander N; Alvar J
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006988. PubMed ID: 30653490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
